[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![YVR_Trader Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1645508869.png) YVR Trader [@YVR_Trader](/creator/twitter/YVR_Trader) on x 10.9K followers
Created: 2025-07-05 02:37:21 UTC

The AI-driven drug discovery market is expected to grow to $7B-$18B by 2030. These platforms can reduce costs by XX% and shorten timelines from years to 12-18 months. Currently Recursion Pharma is valued at $1B, Benevolent AI at over $1.5B and GRAIL at around $3B.   Few realize that $TAO SN68 @metanova_labs is involved in this robustly expanding  market.   This endeavor is being led by @micaelabazo.   MetaNOVA is currently valued at only $10.4M which is  IMO the one of the most undervalued of the XXX subnets.  Keep in mind AI drug discovery platforms will command premium valuations similar to high-growth SaaS companies due to innovation, scalability and cost saving potential.

![](https://pbs.twimg.com/media/GvD3Y-qXcAApKtk.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1941325496098414933/c:line.svg)

**Related Topics**
[tao](/topic/tao)
[1b](/topic/1b)
[$tao](/topic/$tao)
[$3b](/topic/$3b)
[grail](/topic/grail)
[$15b](/topic/$15b)
[$1b](/topic/$1b)
[$18b](/topic/$18b)

[Post Link](https://x.com/YVR_Trader/status/1941325496098414933)